Abstract
Psychotropic drugs, like antipsychotics and antidepressants, are often associated with metabolic side effects such as weight gain and an increased risk of the development of diabetes and an atherogenic lipid profile. These adverse effects not only bear a high cardiovascular risk and lead to higher morbidity and mortality, but are an additional burden to mentally ill patients and can be a decisive factor for the compliance and, consequently, the success of the therapy. Second generation antipsychotics (SGAs), in particular, clozapine and olanzapine, lead to significant weight gain and impair glucose metabolism. Despite the availability of newer SGAs, such as aripiprazole, which are considered to be less prone to cause metabolic side effects, olanzapine is still one of the most prescribed SGAs worldwide. Antidepressant drugs may also induce weight again and diabetes even though the literature is contradictory, probably due to different receptor affinities. This review aims to provide an overview of the metabolic side effects caused by commonly used psychotropic drugs and give insight into underlying mechanisms.
Keywords: Antidepressants, antipsychotics, diabetes, glucose metabolism, insulin resistance, psychotropic drugs, weight gain.
Current Diabetes Reviews
Title:The Effects of Psychotropic Drugs on the Regulation of Glucose Metabolism
Volume: 9 Issue: 5
Author(s): Ramona Al-Zoairy, Claudia Ress, Alexander Tschoner, Susanne Kaser and Christoph Ebenbichler
Affiliation:
Keywords: Antidepressants, antipsychotics, diabetes, glucose metabolism, insulin resistance, psychotropic drugs, weight gain.
Abstract: Psychotropic drugs, like antipsychotics and antidepressants, are often associated with metabolic side effects such as weight gain and an increased risk of the development of diabetes and an atherogenic lipid profile. These adverse effects not only bear a high cardiovascular risk and lead to higher morbidity and mortality, but are an additional burden to mentally ill patients and can be a decisive factor for the compliance and, consequently, the success of the therapy. Second generation antipsychotics (SGAs), in particular, clozapine and olanzapine, lead to significant weight gain and impair glucose metabolism. Despite the availability of newer SGAs, such as aripiprazole, which are considered to be less prone to cause metabolic side effects, olanzapine is still one of the most prescribed SGAs worldwide. Antidepressant drugs may also induce weight again and diabetes even though the literature is contradictory, probably due to different receptor affinities. This review aims to provide an overview of the metabolic side effects caused by commonly used psychotropic drugs and give insight into underlying mechanisms.
Export Options
About this article
Cite this article as:
Al-Zoairy Ramona, Ress Claudia, Tschoner Alexander, Kaser Susanne and Ebenbichler Christoph, The Effects of Psychotropic Drugs on the Regulation of Glucose Metabolism, Current Diabetes Reviews 2013; 9 (5) . https://dx.doi.org/10.2174/15733998113099990067
DOI https://dx.doi.org/10.2174/15733998113099990067 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Towards Human on a Chip: Recent Progress and Future Perspective
Micro and Nanosystems subject Index To Volume 3
Current Drug Targets Stabilization of Neutral NH2-R-COOH Form of the Antihypertensive Peptides L-Valyl-L-Prolyl-L-Proline and L-Isoleucyl-L-Prolyl-L-Proline
Protein & Peptide Letters Hybrid Stress Testing by Adenosine Infusion and Exercise Myocardial Perfusion Imaging: A Critical Appraisal
Current Cardiology Reviews Molecular Mechanisms of Inherited Arrhythmias
Current Genomics A Role for Endothelin-1 in Peripheral Vascular Disease
Current Vascular Pharmacology Current Status and Ongoing Development of Reversing Agents for Novel Oral Anticoagulants (NOACs)
Recent Patents on Cardiovascular Drug Discovery Stem Cells in Cardiovascular Regeneration: From Preservation of Endogenous Repair to Future Cardiovascular Therapies
Current Pharmaceutical Design Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD
Current Pharmaceutical Design Phytoestrogens in Postmenopause: The State of the Art from a Chemical, Pharmacological and Regulatory Perspective
Current Medicinal Chemistry Intracardiac Origin of Heart Rate Variability, Pacemaker Funny Current and their Possible Association with Critical Illness
Current Cardiology Reviews Lipids in the Diet and the Fatty Acid Profile in Beef: A Review and Recent Patents on the Topic
Recent Patents on Food, Nutrition & Agriculture Inhibition of Candida rugosa Lipase by Different Extracts of Five Algerian Plants and their Antioxidant Activities
Current Enzyme Inhibition Nitric Oxide and Dietary Factors: Part II Cholesterol, Fat, Amino Acids,Proteins and Carbohydrate
Vascular Disease Prevention (Discontinued) Early Vascular Ageing (EVA): Definitions and Clinical Applicability
Current Hypertension Reviews The Metabolic Fate of Apple Polyphenols in Humans
Current Nutrition & Food Science Development and Validation of a Stability-Indicating HPLC Method for the Assay of Carvedilol in Pure and Tablet Dosage Forms
Current Pharmaceutical Analysis Managing Safety Signals in Large Endpoint Trials
Current Drug Safety Recent advances in the management of autoimmune myocarditis: insights from animal studies.
Current Pharmaceutical Design Disparities in Cardiovascular Disease Risk in the United States
Current Cardiology Reviews